On the stock market since 2011, it operates in the world of health and science. It has 15 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 83% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 147% a year on average.
Sales run at $1.0M a year. A small number, but proof the product has real buyers.
A loss of $7K against $1.0M in annual sales.
The stock sits at $0.0002. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, NTRR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NTRR is a high-risk stock — not yet profitable, and its future rides on its product catching on.